Mary Eileen Dolan to Neoplasms
This is a "connection" page, showing publications Mary Eileen Dolan has written about Neoplasms.
Connection Strength
2.654
-
Comprehensive association analysis of speech recognition thresholds after cisplatin-based chemotherapy in survivors of adult-onset cancer. Cancer Med. 2023 02; 12(3):2999-3012.
Score: 0.302
-
Clinical and genetic risk factors for radiation-associated ototoxicity: A report from the Childhood Cancer Survivor Study and the St. Jude Lifetime Cohort. Cancer. 2021 Nov 01; 127(21):4091-4102.
Score: 0.279
-
Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors. Clin Cancer Res. 2020 12 15; 26(24):6550-6558.
Score: 0.264
-
Genetic and Modifiable Risk Factors Contributing to Cisplatin-induced Toxicities. Clin Cancer Res. 2019 02 15; 25(4):1147-1155.
Score: 0.230
-
Genome-Wide Association Studies of Chemotherapeutic Toxicities: Genomics of Inequality. Clin Cancer Res. 2017 Aug 01; 23(15):4010-4019.
Score: 0.208
-
Using germline genomics to individualize pediatric cancer treatments. Clin Cancer Res. 2012 May 15; 18(10):2791-800.
Score: 0.148
-
Mixed effects modeling of proliferation rates in cell-based models: consequence for pharmacogenomics and cancer. PLoS Genet. 2012 Feb; 8(2):e1002525.
Score: 0.145
-
The use of genomic information to optimize cancer chemotherapy. Semin Oncol. 2011 Apr; 38(2):186-95.
Score: 0.137
-
The emerging role of microRNAs in drug responses. Curr Opin Mol Ther. 2010 Dec; 12(6):695-702.
Score: 0.133
-
Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin Cancer Res. 2009 Aug 01; 15(15):4806-14.
Score: 0.121
-
Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res. 2008 May 01; 68(9):3161-8.
Score: 0.112
-
Identifying genetic variants that contribute to chemotherapy-induced cytotoxicity. Pharmacogenomics. 2007 Sep; 8(9):1159-68.
Score: 0.107
-
Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumors. Clin Cancer Res. 2002 Aug; 8(8):2519-23.
Score: 0.075
-
Lack of evidence for a polymorphism at codon 160 of human O6-alkylguanine-DNA alkyltransferase gene in normal tissue and cancer. Clin Cancer Res. 1999 Jan; 5(1):209-13.
Score: 0.058
-
Integration of genetic and functional genomics data to uncover chemotherapeutic induced cytotoxicity. Pharmacogenomics J. 2019 04; 19(2):178-190.
Score: 0.056
-
O6-benzylguanine and its role in chemotherapy. Clin Cancer Res. 1997 Jun; 3(6):837-47.
Score: 0.052
-
Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children's Oncology Group. Cancer Chemother Pharmacol. 2014 Oct; 74(4):831-8.
Score: 0.043
-
Cancer pharmacogenomics: strategies and challenges. Nat Rev Genet. 2013 Jan; 14(1):23-34.
Score: 0.038
-
Copy number polymorphisms and anticancer pharmacogenomics. Genome Biol. 2011; 12(5):R46.
Score: 0.034
-
Approaches to the discovery of pharmacogenomic markers in oncology: 2000-2010-2020. Pharmacogenomics. 2010 Apr; 11(4):471-4.
Score: 0.032
-
Use of cell lines in the investigation of pharmacogenetic loci. Curr Pharm Des. 2009; 15(32):3782-95.
Score: 0.029
-
Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer. Clin Cancer Res. 2000 Aug; 6(8):3025-31.
Score: 0.016
-
O6-benzylguanine in humans: metabolic, pharmacokinetic, and pharmacodynamic findings. J Clin Oncol. 1998 May; 16(5):1803-10.
Score: 0.014
-
Sequential therapy with dacarbazine and carmustine: a phase I study. Cancer Chemother Pharmacol. 1994; 34(6):509-14.
Score: 0.010
-
The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther. 2007 Mar; 81(3):328-45.
Score: 0.006
-
Distribution and functional consequences of nucleotide polymorphisms in the 3'-untranslated region of the human Sep15 gene. Cancer Res. 2001 Mar 01; 61(5):2307-10.
Score: 0.004